If Allergan Inc serves as an accurate meter of the economic demand for cosmetic 
surgery, then perhaps things are looking up. First quarter earnings for the pharmaceutical company (maker of Botox, Juvederm and Latisse) are “soaring.” Second quarter forecasts, according to the Wall Street Journal, are ahead of expectations.
The company’s continuing success shouldn’t be surprising, given the statistics just released by the American Society of Plastic Surgeons. According to the society, minimally invasive procedures have increased a whopping 99 percent this decade. Topping the list are wrinkle filler and botulinum toxin injections, two treatments in which plastic surgeons are very likely to utilize an Allergan product.
It doesn’t hurt to be on the cutting-edge of aesthetic medicine either, with the new “no-pain” Juvederm Ultra XC making its way to cosmetic practices across the nation. Not to mention the popularity of Latisse, Allergan’s one-of-a-kind eyelash enhancement drug